Pricing Log in Create free account
Friday 6 November 2026 Export A’s income statement to Excel — free account

Agilent Technologies, Inc.

A Healthcare Diagnostics & Research

Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.

Revenue
+8.06%
EPS
+8.47%
Free cash flow
+69.5%
Total debt
+8.81%

Quarter to July 2026, against a year earlier

171.89 5.28 −2.98%
Market cap
$48.4B
P/E
33.8×
Fwd P/E
34.1×
Dividend yield
0.59%
F-score
5/9
Altman Z
5.46
Beneish M
−2.46
Dividend safety
86/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by segment Fiscal 2025

  • Agilent CrossLab
  • Life Sciences and Diagnostics Markets
  • Applied Markets

Every year since 2009 →

Insider Decisions last twelve months

Sold, $m 0.31
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 1 — — — 1 — —
Insider Ownership 0.34%

Capital & Financial Ratios $m

Size
Market Cap 48,430.00
Revenue ttm 7,372.00
Net income ttm 1,440.00
Free cash flow ttm 1,267.00
Net debt Q 1,887.00
Valuation
P/E 33.77
Forward P/E 34.10
Price / sales 6.58
Forward P/S Powerpack
Price / FCF 38.20
Price / book 6.58 (above 6: high)
Financial health
Current ratio Q 2.05 (at or above 1.5: strong)
Debt / equity Q 0.50 (at or below 0.5: strong)
Interest coverage Q 15.31
Growth
Revenue growth Q +8.06% (above 0%: growing)
Operating income growth Q +23.33% (above 0%: growing)
EPS, this year +10.94%
EPS, next year A +8.04%
Revenue, next year A +7.94%
EPS, past 5 yrs +14.72%
EPS, next 5 yrs A +9.88%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.8×, against a ten-year median of 5.3×; over the ten years it ranged from 3.0× in 2016 to 8.9× in 2021.
P/E against its own 10 years 64.36%
10-year low 10-year high
P/S against its own 10 years 86.14%
10-year low 10-year high
P/B against its own 10 years 68.61%
10-year low 10-year high
EV/Sales against its own 10 years 86.98%
10-year low 10-year high
EV/FCF against its own 10 years 85.00%
10-year low 10-year high

Dividends

Yield
0.59%
Annual rate
1.02
Payout ratio
20.1%
Growth, 2018–26
+6.62%/yr
  1. 0.61 ’18
  2. 0.67 ’19 +10
  3. 0.54 ’20 −20
  4. 0.78 ’21 +44
  5. 1.07 ’22 +37
  6. 0.91 ’23 −14
  7. 0.96 ’24 +5
  8. 0.74 ’25 −22
  9. 1.02 ’26 +37
paid change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,590 1,329 1,789 1,758
Receivables 1,291 1,324 1,487 1,478
Inventory 1,031 972 1,025 1,117
Other 274 334 293 340
4,186 3,959 4,594 4,693
2023 2024 2025 Q'26
Payables 418 540 570 608
ST’ Debt — — — —
Other — — — —
1,603 1,895 2,347 2,289

Compound Annual Growth %

10y 5y 3y
Sales 5.58% 5.41% 0.48%
Cash Flow 11.78% 11.10% 5.92%
Earnings 12.51% 12.63% 1.29%
Book Value 4.92% 6.71% 8.31%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 1.48 Actual 1.62

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 1.59 1.59 Met by 0.00
Q1 FY26 1.37 1.36 Miss by 0.01
Q2 FY26 1.40 1.49 Beat by 0.09
Q3 FY26 1.48 1.62 Beat by 0.14
Q4 FY26 1.72 — Reports 23 November 2026

EPS $

Jan Apr Jul Oct Year
’26 1.07 1.20 1.28 — —
’25 1.11 0.75 1.18 1.53 4.57
’24 1.18 1.05 0.97 1.22 4.43
’23 1.19 1.02 0.38 1.62 4.19
’22 0.93 0.91 1.10 1.23 4.18
’21 0.93 0.70 0.86 1.45 3.94
’20 0.63 0.32 0.64 0.71 2.30
Fiscal quarters ending in the months shown.

Revenue $m

Jan Apr Jul Oct Year
’26 1,798 1,835 1,878 — —
’25 1,681 1,668 1,738 1,861 6,948
’24 1,658 1,573 1,578 1,701 6,510
’23 1,756 1,717 1,672 1,688 6,833
’22 1,674 1,607 1,718 1,849 6,848
’21 1,548 1,525 1,586 1,660 6,319
’20 1,357 1,238 1,261 1,483 5,339
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jan Apr Jul Oct Year
’26 268 277 519 — —
’25 431 221 362 545 1,559
’24 485 333 452 481 1,751
’23 296 398 562 516 1,772
’22 255 283 326 448 1,312
’21 238 472 334 441 1,485
’20 (59) 313 290 377 921
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jan Apr Jul Oct Year
’26 175 201 439 — —
’25 338 107 259 452 1,152
’24 395 230 360 388 1,373
’23 220 341 481 432 1,474
’22 180 219 244 378 1,021
’21 197 441 279 379 1,297
’20 (93) 280 266 350 803
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 16.3% a year for ten years. It grew 9.9% a year over the last ten.

Implied
16.3%
10 years, reported
9.9%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to October

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jul ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 4,202 4,472 4,914 5,163 5,339 6,319 6,848 6,833 6,510 6,948 7,372 +5.7% 7,500 7,981 8,523 +7.0%
Gross margin, % 52.28 53.64 54.54 54.33 53.14 53.92 54.35 50.71 54.30 52.43 53.83 +0.1 pt
EBT 544 803 946 919 842 1,360 1,504 1,339 1,521 1,435 1,658 +11.4%
EBT margin, % 12.95 17.96 19.25 17.80 15.77 21.52 21.96 19.60 23.36 20.65 22.49 +7.7 pt
Net income 462 684 316 1,071 719 1,210 1,254 1,240 1,289 1,303 1,440 +12.2%
Per share, $
Per share, $ Revenue 12.89 13.89 15.31 16.44 17.28 20.79 22.90 23.24 22.45 24.46 26.14 +7.4%
Earnings 1.41 2.12 0.98 3.41 2.33 3.98 4.19 4.22 4.44 4.59 5.09 +14.0%
Cash flow 2.43 2.76 3.39 3.25 2.98 4.88 4.39 6.03 6.04 5.49 5.71 +9.5%
Capex (0.43) (0.55) (0.55) (0.50) (0.38) (0.62) (0.97) (1.01) (1.30) (1.43) (1.21) +14.4%
Free cash flow 2.01 2.21 2.84 2.75 2.60 4.27 3.41 5.01 4.73 4.06 4.49 +8.1%
Book value 13.02 15.02 14.24 15.12 15.77 17.73 17.74 19.88 20.34 23.74 26.11 +6.9%
Shares, m 326 322 321 314 309 304 299 294 290 284 283 (1.5%)
Valuation, ×
Valuation, × P/E 30.90 31.94 64.79 22.35 45.17 39.46 32.94 24.50 29.35 31.96 33.77 35.3
P/S 3.38 4.90 4.23 4.61 6.09 7.56 6.04 4.45 5.80 5.98 6.58 5.3
P/B 3.35 4.53 4.55 5.01 6.67 8.86 7.80 5.20 6.41 6.17 6.58 5.9
EV/Sales 3.29 4.70 4.14 4.69 6.25 7.74 6.29 4.62 6.11 6.16 6.83 5.4
EV/FCF 21.13 29.49 22.34 27.94 41.55 37.76 42.29 21.44 29.06 37.11 39.68 31.0
Cash, $m
Cash, $m Operating cash flow 793 889 1,087 1,021 921 1,485 1,312 1,772 1,751 1,559 1,609 +7.8%
Capex (139) (176) (176) (156) (118) (188) (291) (298) (378) (407) (342) +12.7%
Free cash flow 654 713 911 865 803 1,297 1,021 1,474 1,373 1,152 1,267 +6.5%
Balance, $m
Balance, $m Working capital 2,690 2,906 2,677 1,109 1,948 2,091 1,917 2,583 2,064 2,247 2,404 (2.0%)
Net debt (385) (877) (448) 409 843 1,154 1,680 1,145 2,016 1,261 1,887 n/m
Shareholders’ equity 4,246 4,835 4,571 4,748 4,873 5,389 5,305 5,845 5,898 6,741 7,363 +5.3%
Returns, %
Returns, % ROA 6.05 8.43 3.72 11.90 7.54 11.90 11.81 11.65 11.40 10.61 11.00 +4.6 pt
ROIC 9.96 12.74 13.70 11.40 9.25 12.87 14.48 12.07 11.75 11.55 11.07 +1.6 pt
ROE 10.98 15.06 6.72 22.99 14.95 23.58 23.45 22.24 21.95 20.62 20.97 +9.6 pt
People
People Employees 12,500 13,500 14,800 16,300 16,400 17,000 18,100 18,100 17,900 18,100 — +4.2%
Revenue/emp, $m 0.34 0.33 0.33 0.32 0.33 0.37 0.38 0.38 0.36 0.38 — +1.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Oct 2025 · latest quarter Jul 2026

Business profile

Updated

Agilent Technologies is a laboratory-tools company serving life sciences, diagnostics and applied markets. It was founded in 1999, is headquartered in Santa Clara, and is led by President and Chief Executive Officer Padraig McDonnell.

The company supplies the equipment, materials and support used to prepare, test and interpret laboratory samples. Its offerings include instruments, software, services and consumables across laboratory workflows. Life Sciences and Diagnostics Markets sells liquid chromatography and mass-spectrometry systems, cell-analysis tools, pathology products, genomics reagents, companion-diagnostic development services, biomolecular-analysis tools, and contract development and manufacturing services for oligonucleotide active pharmaceutical ingredients.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
Agilent CrossLab 2,908 41.85%
Life Sciences and Diagnostics Markets 2,726 39.23%
Applied Markets 1,314 18.91%
Gross margin 52.43%
Operating margin 21.29%
Pre-tax margin 20.65%

Revenue by segment since 2009

Agilent Technologies, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IDXX IDEXX Laboratories, Inc. $52.8B 44.8× 37.3× +9.86% (above 0%: growing) +17.30% (above 0%: growing) +17.58% (above 0%: growing) 62.94% 33.14% Compare
NTRA Natera, Inc. $52.4B — (loss-making) — (loss-making) +34.08% (above 0%: growing) n/m −85.80% (below 0%: shrinking) 0.00% (8.60%) Compare
A Agilent Technologies, Inc. $48.4B 33.8× 34.1× +8.06% (above 0%: growing) +8.47% (above 0%: growing) +69.50% (above 0%: growing) 55.48% 23.64%
WAT Waters Corporation $44.5B 194× 81.0× +120.91% (above 0%: growing) −67.02% (below 0%: shrinking) −66.71% (below 0%: shrinking) 50.25% 7.24% Compare
IQV IQVIA Holdings Inc. $43.7B 31.8× 34.8× +8.00% (above 0%: growing) +10.16% (above 0%: growing) −21.25% (below 0%: shrinking) 33.83% 12.92% Compare
MTD Mettler-Toledo International, Inc. $33.6B 37.6× 36.1× +4.48% (above 0%: growing) +18.30% (above 0%: growing) +33.01% (above 0%: growing) 63.29% 30.61% Compare
ILMN Illumina, Inc. $31.5B 35.6× 46.4× +4.15% (above 0%: growing) +48.98% (above 0%: growing) +49.80% (above 0%: growing) 73.52% 27.02% Compare
LH Labcorp Holdings Inc. $29.5B 29.5× 26.7× +6.92% (above 0%: growing) +3.18% (above 0%: growing) +44.73% (above 0%: growing) 29.08% 10.55% Compare
DGX Quest Diagnostics Incorporated $28.0B 25.0× 24.4× +9.98% (above 0%: growing) +29.36% (above 0%: growing) +6.21% (above 0%: growing) 33.65% 15.47% Compare
Median of peers $38.6B 35.6× 36.1× +8.93% +17.30% +11.90% 42.04% 14.20%

All 49 Diagnostics & Research stocks →

From the latest earnings call

Updated

  • Parag McDonnell said Q3 demand improved across pharma, chemicals and advanced materials, diagnostics and clinical, with China revenue growing 9%.
  • Adam Elanoff said Agilent raised its FY2026 outlook, while Q4 Advanced Therapeutics Division growth is expected to be flat against a comparison exceeding 40%.

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 91.90%
Held by the ten largest 44.45%
Holder Shares Stake Change
Vanguard 35.83m 12.69% +209.73k
BlackRock 25.60m 9.06% −303.66k
State Street 12.85m 4.55% +89.60k
MFS Investment Management 10.01m 3.54% −2.61m
T. Rowe Price 8.77m 3.11% −633.99k
Geode Capital Management 7.60m 2.69% +73.62k
Wellington Management 7.45m 2.64% +198.25k
Deutsche Bank (DWS) 7.01m 2.48% +1.02m
BNY 5.23m 1.85% +2.44m
Morgan Stanley 5.19m 1.84% +236.61k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 6 February 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 12.83m 14.64m 148.32
2023 16.02m 1.01m 103.21
2022 16.65m 10.46m 137.17
2021 15.97m 31.77m 155.15

Ownership

Directors and executive officers, together less than 1%
The Vanguard Group 11.80%
BlackRock, Inc. 8.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Agilent Technologies, Inc. (A) Latest News

4 Nov

Impact 3 · · Business Wire

29 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Business Wire
Impact 3 · · Simply Wall St.

28 Oct

Impact 4 · · Barchart
Impact 3 · · StockStory

27 Oct

Impact 4 · · Business Wire

20 Oct

Impact 3 · · Zacks

14 Oct

Impact 4 · · medicaldevice-network.com
Impact 4 · · medtechdive.com

13 Oct

Impact 4 · · Business Wire

12 Oct

Impact 3 · · Zacks

8 Oct

Impact 3 · · Simply Wall St.

1 Oct

Impact 4 · · Business Wire

29 Sep

Impact 3 · · Business Wire

27 Sep

Impact 3 · · Simply Wall St.

25 Sep

Impact 4 · · Zacks

23 Sep

Impact 4 · · Zacks
Impact 4 · · MarketBeat

21 Sep

Impact 4 · · Business Wire

19 Sep

Impact 3 ·

4 Sep

Impact 3 ·

1 Sep

Impact 3 ·

31 Aug

Impact 3 · · The Motley Fool transcript
Impact 3 ·

28 Aug

Impact 3 ·

27 Aug

Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 · · Moby transcript

A metrics, ten years each

stockrow.com/A · Data as of Jul 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com